文献速递新发突发、热带与寄生虫病

疟疾药物试验的PCR校正策略:更新与澄清

PCR correction strategies for malaria drug trials: updates and clarifications.
PubMed 文献 · Lancet Infect Dis · 2019-09-17

在疟疾流行区开展的药物试验中,治疗后血样中的寄生虫血症难以区分是药物失败还是新发感染,需通过比较治疗前与复发日恶性疟原虫基因型进行PCR校正。该文讨论基因分型方法的最新进展、验证与局限性,呼吁采用改进的标准化PCR校正方法。

要点

  • PCR校正是准确估计疟疾药物失败率的关键,即使对新型有效药物也需进行。
  • 通过比较基线及复发日恶性疟原虫基因型可区分药物失败与新发感染。
  • 当前基因分型方法存在局限性,需推动标准化PCR校正方法的采用。

核心结论

  • PCR校正对于获得准确的疟疾药物失败率至关重要,但现有分子基因分型方法的局限性引发对其有效性的质疑,需采用改进的标准化方法。

研究设计与样本

  • 本文为综述性文章,描述并讨论用于疟疾药物试验PCR校正的基因分型方法的最新进展,聚焦方法验证与分型策略的局限性。

主要发现

  • 在疟疾流行区,治疗后寄生虫血症难以区分药物失败与新发感染,通过比较治疗前与复发日恶性疟原虫基因型可实现区分。
  • 尽管PCR校正已常规用于耐药监测和临床试验,但分子基因分型方法固有的局限性使部分研究者对现行校正策略的有效性提出疑问。

临床怎么用

  • 在疟疾药物试验和耐药监测中,应规范开展PCR校正以准确评估药物失败率,并关注基因分型方法的验证与标准化。

局限性

  • 分子基因分型方法本身存在局限性,可能影响PCR校正策略的有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malaria drug trials conducted in endemic areas face a major challenge in their analysis because it is difficult to establish whether parasitaemia in blood samples collected after treatment indicate drug failure or a new infection acquired after treatment. It is therefore vital to reliably distinguish drug failures from new infections in order to obtain accurate estimates of drug failure rates. This distinction can be achieved for Plasmodium falciparum by comparing parasite genotypes obtained at the time of treatment (the baseline) and on the day of recurring parasitaemia. Such PCR correction is required to obtain accurate failure rates, even for new effective drugs. Despite the routine use of PCR correction in surveillance of drug resistance and in clinical drug trials, limitations inherent to the molecular genotyping methods have led some researchers to question the validity of current PCR correction strategies. Here we describe and discuss recent developments in these genotyping approaches, with a particular focus on method validation and limitations of the genotyping strategies. Our aim is to update scientists from public and private bodies who are working on the development, deployment, and surveillance of new malaria drugs. We aim to promote discussion around these issues and argue for the adoption of improved standardised PCR correction methodologies.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Felger I, Snounou G, Hastings I, et al. PCR correction strategies for malaria drug trials: updates and clarifications. Lancet Infect Dis. 2019. PMID: 31540841. doi:10.1016/S1473-3099(19)30426-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。